Navigation Links
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Date:1/31/2008

e mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (ie, bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON(TM). Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON(TM).

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON(TM) but similar to INTRON(R) A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON(TM).

The following serious or clinically significant adverse events have been reported at a frequency less than or equal to 1% with PEGINTRON(TM) or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

Additional Safety Information

Relapse of drug addiction/overdose has occurred in patients on PEGINTRON(TM) therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON(TM) and/or INTRON(R) A treatment and follow-up.

If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON(TM) and
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... th Annual Canaccord|Genuity Growth Conference in ... and CEO, William C. Taylor , President and ...
(Date:8/3/2015)... DOVER, Delaware , August 3, 2015 ... engaged in the commercialization of its Bio-electrical Signal Therapy ... the noninvasive treatment of hard to heal chronic wounds, ... distribution agreement with Chemipal, an Israeli distributor specializing in ... BST device. Chemipal is a 70 years ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... will potentially enable access to MRI exams for ... implantable cardiac ... Boston,Scientific Corporation (NYSE: BSX ) and Surgi-Vision, ... development arrangement for,magnetic resonance imaging (MRI)-safe technology. Physician implanters ...
... ... 2008, FT. MYERS, Fla., April 15 ... the,Securities and Exchange Commission its annual report on Form 10-KSB for the,year ended ... http://www.SEC.gov ., The audited financial statements for the year ended December ...
... April 15 Arpida Ltd.,(SWX: ARPN) today announced ... Thursday,17 April 2008 at 8.30am CET. In this ... need and developments in the area of anti-infective,drugs ... meeting of the Anti-Infective,Drugs Advisory Committee. During that ...
Cached Biology Technology:Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology 2Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology 3NeoGenomics Files Annual Report on Form 10-KSB with the SEC 2Arpida Announces Conference Call on 17 April 2Arpida Announces Conference Call on 17 April 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... be placing their unborn children at increased risk of ... of construction workers in the Netherlands, conducted in part ... low birth weight and birth defects to paternal, airborne ... cleansers. , The study, although preliminary in its parent-reported ...
... on the eyes" may hit closer to the mark than ... the University of California, San Diego, and published in the ... depend on mental processing ease, or being "easy on the ... what your mind has been trained on," Winkielman said. "A ...
... human infants have located the source of a 30-year-old mystery ... , Scientists have known of the mouse line's naturally occurring ... of Medicine in St. Louis are the first to identify ... and the origins of the disease. , "The gene ...
Cached Biology News:Solvent exposure linked to birth defects in babies of male painters 2Beauty and the brain 2Beauty and the brain 3Scientists solve 30-year-old mystery of mutant mouse's kidney woes 2Scientists solve 30-year-old mystery of mutant mouse's kidney woes 3